News - Page 155 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

Post published:August 24, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan

Post published:August 24, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question

Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question

Post published:August 20, 2021
Post category:Psychedelic Bulletin

Read more about the article Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs

Post published:August 19, 2021
Post category:Press Release

Read more about the article Wesana Health Highlights Recent Appointments to Board of Directors

Wesana Health Highlights Recent Appointments to Board of Directors

Post published:August 19, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor

Post published:August 18, 2021
Post category:Press Release

Read more about the article Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

Post published:August 18, 2021
Post category:Press Release

Read more about the article Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine

Mydecine Innovations Group signs five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine

Post published:August 18, 2021
Post category:Press Release

Read more about the article Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its Work on the AME-1

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its Work on the AME-1

Post published:August 17, 2021
Post category:Press Release

Read more about the article Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin

Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin

Post published:August 17, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.